Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on Johnson & Johnson

Share:
Related JNJ
10 Companies With The Best Corporate Reputations
Icahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer?
Seeking Alpha Interviews: Bret Jensen On Promising Drugs And Acquisition Targets (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Hold rating on Johnson & Johnson (NYSE: JNJ), and raised its price target from $75.00 to $79.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Johnson & Johnson closed on Tuesday at $72.56.

Latest Ratings for JNJ

DateFirmActionFromTo
Jan 2017Wells FargoDowngradesOutperformMarket Perform
Nov 2016BarclaysDowngradesOverweightEqual-Weight
Sep 2016JefferiesMaintainsHold

View More Analyst Ratings for JNJ
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (JNJ)

View Comments and Join the Discussion!